The serrated adenocarcinoma cases presenting with a residual adenoma component undoubtedly showed KRAS mutations (57.1%) to be twice as frequent as BRAF mutations (28.6%) in serrated adenocarcinomas. The gene discussed is KRAS; the disease is adenoma.